KaNDy Therapeutics Company Profile

18:33 EDT 19th October 2018 | BioPortfolio

News Articles [782 Associated News Articles listed on BioPortfolio]

KaNDy Therapeutics reports positive data in RELENT-1 study

UK-based biotech company KaNDy Therapeutics has reported positive results from the Phase Ib/IIa RELENT-1 clinical trial of NT-814 to treat...Read More... The post KaNDy Therapeutics reports positive d...

UK's KaNDy Therapeutics funds mid-stage trial of HRT 'replacement'

UK biotech KaNDy Therapeutics has closed a third funding round, raising a further £25 million to take its non-hormonal drug candidate NT-814 for menopause symptoms through to phase 3 and a potential ...

KaNDy Therapeutics raises £25m to advance non-hormonal drug candidate

KaNDy is focused on optimizing the potential of NT-814 as a non-hormonal treatment for common, chronic debilitating female sex-hormone associated conditions. The funding came from new US investor The...

UK-based KaNDy Therapeutics raises $32.5 million Series C round, led by US firm

Longitude Capital leads round worth £25 million, which KaNDy will use to advance its non-hormonal menopause drug into Phase IIb

Sweetening the pot

Why KaNDy Therapeutics spun out of NeRRe to develop its non-hormonal therapy for menopausal symptoms.

Investors Sweet On KaNDy Menopause Treatment

Armed with a fresh injection of £25m, the UK's KaNDy is about to begin Phase IIb trials of a dual...    

Women’s health biotech raises €28M to fund Phase II menopause drug trial

UK-biotech KaNDy Therapeutics closed a £25M (€28M) series C round to help finance the upcoming Phase IIb trial of its lead candidate for treating symptoms of the menopause. Unlike other therapies a...

KaNDy Therapeutics Announces Positive Clinical Data with Lead Candidate NT-814 for the Treatment of Symptoms of the Menopause

~Phase Ib/IIa data showed rapid and highly significant reductions in the frequency and severity of hot flashes and the number of night time awakenings~ ~NT-814 is ...

PubMed Articles [448 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

The association between local meteorological changes and exacerbation of acute wheezing in Kandy, Sri Lanka.

Severe wheezing is a common medical emergency. Past studies have demonstrated associations between exacerbation of wheezing and meteorological factors and atmospheric pollution. There are no past stud...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [157 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1263 Associated Companies listed on BioPortfolio]

KaNDy Therapeutics

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "KaNDy Therapeutics" on BioPortfolio

We have published hundreds of KaNDy Therapeutics news stories on BioPortfolio along with dozens of KaNDy Therapeutics Clinical Trials and PubMed Articles about KaNDy Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of KaNDy Therapeutics Companies in our database. You can also find out about relevant KaNDy Therapeutics Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record